NCT07863765
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07863765
Title Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Northwestern University
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Northwestern University Chicago Illinois 60611 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field